Multidisciplinary Management of Hepatocellular Carcinoma

被引:47
作者
Guy, Jennifer [1 ]
Kelley, Robin K. [1 ,2 ]
Roberts, John [3 ,4 ]
Kerlan, Robert [5 ,6 ]
Yao, Francis [1 ]
Terrault, Norah [1 ]
机构
[1] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[2] Univ Calif San Francisco, Div Oncol, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA
[4] Univ Calif San Francisco, Div Transplant Surg, San Francisco, CA 94143 USA
[5] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA
[6] Univ Calif San Francisco, Div Intervent Radiol, San Francisco, CA 94143 USA
关键词
Hepatocellular Carcinoma; Resection; Transplantation; TO-TREAT ANALYSIS; DONOR LIVER-TRANSPLANTATION; LONG-TERM SURVIVAL; RADIOFREQUENCY ABLATION; UNITED-STATES; TRANSARTERIAL CHEMOEMBOLIZATION; REASONABLE STRATEGY; PROGNOSTIC-FACTORS; SURGICAL-TREATMENT; RANDOMIZED-TRIALS;
D O I
10.1016/j.cgh.2011.11.008
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Hepatocellular carcinoma is a leading cause of death in patients with cirrhosis. Management algorithms continually are increasing in sophistication and involve application of single and multimodality treatments, including liver transplantation, hepatic resection, ablation, transarterial chemoembolization, radioembolization, and systemic chemotherapy. These treatments have been shown to increase survival times. As many as 75% of patients with limited-stage disease who are given curative therapies survive 5 years, whereas less than 20% of untreated patients survive 1 year. Treatment can be optimized based on the patient's tumor stage, hepatic reserve, and functional status. However, because of the heterogeneity in presentation among patients, a multidisciplinary approach is required to treat hepatocellular carcinoma, involving hepatologists, surgeons, interventional radiologists, and oncologists. We present each specialist's viewpoint on controversies and advances in the management of hepatocellular carcinoma.
引用
收藏
页码:354 / 362
页数:9
相关论文
共 83 条
[1]
Adam R, 2003, ANN SURG, V238, P508, DOI 10.1097/01.sla.0000090449.87109.44
[2]
Resection prior to liver transplantation for hepatocellular carcinoma [J].
Beighiti, J ;
Cortes, A ;
Abdalla, EK ;
Régimbeau, JM ;
Prakash, K ;
Durand, F ;
Sommacale, D ;
Dondero, F ;
Lesurtel, M ;
Sauvanet, A ;
Farges, O ;
Kianmanesh, R .
ANNALS OF SURGERY, 2003, 238 (06) :885-892
[3]
Intention-to-Treat Analysis of Liver Transplantation for Hepatocellular Carcinoma: Living Versus Deceased Donor Transplantation [J].
Bhangui, Prashant ;
Vibert, Eric ;
Majno, Pietro ;
Salloum, Chady ;
Andreani, Paola ;
Zocrato, Joao ;
Ichai, Philippe ;
Saliba, Faouzi ;
Adam, Rene ;
Castaing, Denis ;
Azoulay, Daniel .
HEPATOLOGY, 2011, 53 (05) :1570-1579
[4]
Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[5]
Major achievements in hepato cellular carcinoma [J].
Bruix, Jordi ;
Llovet, Josep M. .
LANCET, 2009, 373 (9664) :614-616
[6]
A Meta-Analysis of Survival Rates of Untreated Patients in Randomized Clinical Trials of Hepatocellular Carcinoma [J].
Cabibbo, Giuseppe ;
Enea, Marco ;
Attanasio, Massimo ;
Bruix, Jordi ;
Craxi, Antonio ;
Camma, Calogero .
HEPATOLOGY, 2010, 51 (04) :1274-1283
[7]
Multimodal approaches to the treatment of hepatocellular carcinoma [J].
Cabibbo, Giuseppe ;
Latteri, Federica ;
Antonucci, Michela ;
Craxi, Antonio .
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2009, 6 (03) :159-169
[8]
Economic evaluation of sorafenib in unresectable hepatocellular carcinoma [J].
Carr, Brian I. ;
Carroll, Stuart ;
Muszbek, Noemi ;
Gondek, Kathleen .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 (11) :1739-1746
[9]
A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma [J].
Chen, MS ;
Li, JQ ;
Zheng, Y ;
Guo, RP ;
Liang, HH ;
Zhang, YQ ;
Lin, XJ ;
Lau, WY .
ANNALS OF SURGERY, 2006, 243 (03) :321-328
[10]
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34